PriceTargets.com logo

Metagenomi - MGX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.40
  • Forecasted Upside: 184.20%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$7.53 As of 04/26/2024 01:00 AM ET
▲ +0.79 (11.72%)

This chart shows the closing price for MGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Metagenomi Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGX

Analyst Price Target is $21.40
▲ +184.20% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Metagenomi in the last 3 months. The average price target is $21.40, with a high forecast of $25.00 and a low forecast of $16.00. The average price target represents a 184.20% upside from the last price of $7.53.

This chart shows the closing price for MGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Metagenomi. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2024Chardan CapitalReiterated RatingBuy ➝ Buy$21.00Low
3/5/2024TD CowenInitiated CoverageOutperformLow
3/5/2024BMO Capital MarketsInitiated CoverageOutperform$22.00Low
3/5/2024JPMorgan Chase & Co.Initiated CoverageOverweight$16.00Low
3/5/2024Jefferies Financial GroupInitiated CoverageBuy$23.00Low
3/5/2024Chardan CapitalInitiated CoverageBuy$21.00Low
3/5/2024Wells Fargo & CompanyInitiated CoverageOverweight$25.00Low
(Data available from 4/28/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Metagenomi logo
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Read More

Today's Range

Now: $7.53
Low: $6.66
High: $7.69

50 Day Range

MA: $10.35
Low: $6.68
High: $12.20

52 Week Range

Now: $7.53
Low: $6.50
High: $12.74

Volume

139,371 shs

Average Volume

109,835 shs

Market Capitalization

$282.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Metagenomi?

The following Wall Street sell-side analysts have issued stock ratings on Metagenomi in the last twelve months: BMO Capital Markets, Chardan Capital, Jefferies Financial Group Inc., JPMorgan Chase & Co., TD Cowen, and Wells Fargo & Company.
View the latest analyst ratings for MGX.

What is the current price target for Metagenomi?

5 Wall Street analysts have set twelve-month price targets for Metagenomi in the last year. Their average twelve-month price target is $21.40, suggesting a possible upside of 184.2%. Wells Fargo & Company has the highest price target set, predicting MGX will reach $25.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $16.00 for Metagenomi in the next year.
View the latest price targets for MGX.

What is the current consensus analyst rating for Metagenomi?

Metagenomi currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGX will outperform the market and that investors should add to their positions of Metagenomi.
View the latest ratings for MGX.

What other companies compete with Metagenomi?

Other companies that are similar to Metagenomi include Fennec Pharmaceuticals, Invivyd, Black Diamond Therapeutics, Monte Rosa Therapeutics and Anavex Life Sciences. Learn More about companies similar to Metagenomi.

How do I contact Metagenomi's investor relations team?

Metagenomi's physical mailing address is Floor 7, 5959 Horton Street, Emeryville, CA 94608, United States, . The company's listed phone number is 510-871-4880 and its investor relations email address is [email protected]. The official website for Metagenomi is www.metagenomi.co. Learn More about contacing Metagenomi investor relations.